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ABSTRACT
Cancer stem cells (CSCs) are a sub-population of tumor cells playing essential 
roles in initiation, differentiation, recurrence, metastasis and development of drug 
resistance of various cancers, including bladder cancer. Although multiple lines of 
evidence suggest that metformin is capable of repressing CSC repopulation in different 
cancers, the effect of metformin on bladder cancer CSCs remains largely unknown. 
Using the N-methyl-N-nitrosourea (MNU)-induced rat orthotropic bladder cancer 
model, we demonstrated that metformin is capable of repressing bladder cancer 
progression from both mild to moderate/severe dysplasia lesions and from carcinoma 
in situ (CIS) to invasive lesions. Metformin also can arrest bladder cancer cells in 
G1/S phases, which subsequently leads to apoptosis. And also metformin represses 
bladder cancer CSC repopulation evidenced by reducing cytokeratin 14 (CK14+) and 
octamer-binding transcription factor 3/4 (OCT3/4+) cells in both animal and cellular 
models. More importantly, we found that metformin exerts these anticancer effects by 
inhibiting COX2, subsequently PGE2 as well as the activation of STAT3. In conclusion, 
we are the first to systemically demonstrate in both animal and cell models that 
metformin inhibits bladder cancer progression by inhibiting stem cell repopulation 
through the COX2/PGE2/STAT3 axis.
INTRODUCTION
Bladder cancer is the sixth most common cancer 
in the US [1] and about 90% of them are urothelial 
carcinomas with muscle-invasive lesions, papillary lesions 
and CIS; while the other 10% are distributed between 
squamous cell carcinoma (SCC) and adenocarcinoma 
[2, 3]. Although both CIS and papillary lesions belong 
to superficial urothelial carcinomas, they show different 
morphologies as well as invasive potentials. Therefore, it 
has been suggested that CIS and papillary lesions arise 
from different cell types or harbor distinct mutations [4-
16]. Indeed, supportive evidence has shown that both 
CIS and invasive urothelial carcinoma arise from basal 
cells, whereas intermediate cells serve as the progenitors 
of papillary carcinomas [17]. In addition and similar 
to that epithelial tumors constitute heterogeneous cell 
populations [18], while bladder cancer comprises cells at 
different differentiation stages [8, 12]. Cells expressing 
CK14 were considered the least differentiated population, 
which are also known as CSC or tumor initial cells (TIC). 
More importantly, it has been demonstrated that elevated 
levels of CK14+ cells correlate with poor survival [19]. 
Accumulating evidence also supports the notion that CSCs 
are responsible for tumor initiation, relapse, metastasis, as 
well as chemo- and radio-resistance [20]. A recent study 
[21] demonstrated that ablation of basal stem cells is 
capable of preventing bladder cancer development. Given 
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the fact that CSCs are mainly derived from basal stem 
cells, CSCs are likely to play a pivotal role in bladder 
cancer initiation and progression.
Although metformin is mainly considered as a 
antidiabetic agent [22], it has also showed anticancer effect 
in many cancer types, including melanoma [23], colon 
cancer [24], ovarian cancer [25], prostate cancer [26] and 
bladder cancer [27] by enhancing cancer cell apoptosis, 
inhibiting epithelial to mesenchymal transition (EMT) and 
targeting cancer stem cells. These effects were evidenced 
by the fact that metformin can also synergize with certain 
chemotherapeutic drugs [28-33]. For example, metformin 
not only inhibits breast tumor cell growth [34, 35] but also 
selectively represses the CSCs [31]. Results from bladder 
cancer research suggest that metformin may be capable 
of inhibiting cancer cell growth [36] and blocking tumor 
progression from precancerous to invasive tumors [37].
Upregulated cyclooxygenase-2 (COX-2), a key 
enzyme in prostaglandin E2 (PGE2) biosynthesis 
pathway, has been reported in different cancers including 
bladder cancer [38, 39]. In N-butyl-4-N-(4-hydroxybutyl) 
nitrosamine (BBN)-induced rat urinary bladder cancer 
model, COX-2 is also upregulated in both pre-neoplastic 
and neoplastic lesions [40] and elevated expression of 
COX-2 is correlated with higher levels of PGE2 in many 
cancers [41]. Furthermore, it appears that PGE2 plays 
important roles in CSC repopulation of different cancers 
including bladder cancer [42, 43]. Mechanistically, 
COX2/PGE2 is likely to play an important role in CSC 
repopulation through activating the JAK2 (Janus kinase 2)/
STAT3 (signal transducer and activator of transcription 3) 
signaling pathway [44]. Accumulating evidence indicates 
that alterations in JAK/STAT pathway are involved in 
oncogenesis [45]. In liver tumor initiation, the STAT3-
upregulated NANOG CD24+ (cluster of differentiation 
24+) CSCs is believed to play an important role [46]. 
Finally, in Stat3-transgenic mice with BBN-induced 
bladder cancer, an early expansion of CK14+ stem cells 
has been observed [47]. In this research, we demonstrated 
that metformin is capable of repressing bladder cancer 
CSC repopulation through inhibiting the COX2/PGE2/
STAT3 axis in both animal and cellular models.
RESULTS
Effects of metformin on bladder cancer 
development
We decided to use the MNU (N-methyl-N-
nitrosourea)-induced rat orthotopic bladder cancer model 
to examine if metformin (MET) has any effect on bladder 
cancer initiation and progression. The experimental 
scheme is shown in Figure 1A and the general features of 
the MNU-induced bladder cancer treated with or without 
MET were shown in Supplementary Table S1, S2, and 
S3. Figure 1B–1D showed the pathological changes of 
bladder tumors in rat model treated with or without MET. 
The average numbers of lesions in animals treated with 
and without metformin were plotted (Figure 1E). As 
shown in Figure 1E (left pane) that at week 3, the total 
number of mild dysplasia lesions in MNU and MET 
groups were comparable (24 lesions/10 rats in the MNU 
group vs 28 lesions/10 rats in the MET group, P=0.466). 
However, the number of moderate/severe dysplasia 
lesions in animals treated with metformin (MET group, 
16/10 rats) is significantly lower than that in MNU group 
(36/10 rats) (P=0.007). At week 6 (Figure 1E, middle 
panel), metformin treatment increased the number of mild 
dysplasia lesions significantly with 29 mild dysplasia 
lesions/8 rats in MET group compared with 15 lesions/8 
rats in MNU group (P=0.026); but decreased the number 
of moderate/severe dysplasia lesions dramatically with 5 
moderate/severe dysplasia in MET group compared with 
30 lesions/8 rats in MNU group (P=0.02). In addition, 3 
CIS lesions were also seen in the MNU group with none 
of such lesion in the MET group. At week 12 (Figure 
1E, right pane), there were more papillary tumor lesions 
in MET group than that of MNU group (53 lesions/20 
rats in MET group vs 19 lesions/14 rats in MNU group, 
P=0.03). However, the invasive lesions in MET group 
(46 invasive lesions/20 rats) are significantly less than 
that of MNU group (49 lesions/14 rats) (P=0.034). These 
data altogether suggest that metformin may not be able 
to inhibit bladder cancer initiation but be capable of 
repressing the progression from mild to moderate/severe 
dysplasia lesions and from CIS to invasive lesions.
Metformin inhibits cancer cell growth and 
enhances apoptosis
Next, we decided to use bladder cancer cell 
lines to dissect the mechanisms of metformin effects 
on cancer progression. To test if metformin can affect 
bladder cancer cell growth, we treated two bladder 
cancer cell lines T24 and RT4 with or without 20 mM 
of metformin for 5 days and the numbers of viable cells 
were estimated by MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide). Figure 2A shows 
that metformin is able to inhibit both T24 (left panel) 
and RT4 (right panel) cell growth. AMPK (Adenosine 
Monophosphate Activated Protein Kinase) is a well-
established molecular target of metformin [33, 35]. We 
estimated the levels of the phosphorylated AMPK in T24 
cells treated with different concentrations of metformin. 
Figure 2B shows that metformin is capable of upregulating 
the phosphorylation of AMPK in a dose-dependent 
manner without affecting the level of total AMPK. In 
addition, results from western blotting assays showed that 
metformin is capable of repressing the levels of cyclin D1 
and Bcl-2 in both cell lines in a dose-dependent manner 
(Figure 2C). Then, we estimated the effect of metformin 
on cell cycles distribution by treating T24 cells with 
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different concentrations of metformin. Figure 2D shows 
that metformin treatment increased the cell populations 
in G1/S phases and decreased the population in G2 
phase. Furthermore, the apoptotic cell populations were 
upregulated by metformin in a dose-dependent manner 
(Figure 2E). More importantly, immunohistochemical 
staining showed the expression of Ki67 (Figure 3A) and 
Bcl-2 (Figure 3B) in bladder specimens were significantly 
repressed by metformin treatment. Of note, not only the 
intensity of Ki67 but also the numbers of Ki67-positive 
cells were significantly reduced in metformin-treated 
group at all time points (Supplementary Table S4 and 
Figure 1: Effects of metformin on bladder cancer development. A. The experimental scheme of cancer induction and metformin 
treatment. B–D. The effects of metformin on bladder cancer initiation and progression. Bladder tissues from the animals treated with or 
without metformin were collected and stained with H&E at week 3 (B), week 6 (C) and week 12 (D). E. The numbers of different lesions 
in each animal at different time points were counted and the averages of lesions in the animals treated with and without metformin were 
plotted. (B–D) Magnifications: X400.
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Figure 2: Effects of metformin on bladder cancer proliferation and apoptosis. A. T24 and RT4 cells were seeded in 96-
well plates with 0.5×105 cells per well in growth media with or without metformin (20mM) and cultured for 5 days. Cell viabilities were 
estimated by MTT every other day. B. T24 cells were treated with different concentrations of metformin (0, 1, 5, 10 and 20 mM) for 24 h. 
The levels of total AMPK and phosphorylated AMPK were estimated by western blot assays. C. The effects of metformin on the levels of 
Bcl-2 and CyclinD1 were measured by western blotting when T24 and RT4 cells were treated with increasing concentrations of metformin. 
D. and E. T24 cells were treated with different concentrations of metformin and the numbers of cells at different stages of cycle were 
analyzed by flow cytometry (D), or stained with PI and FITC-labelled Annexin V and subsequently underwent flow cytometry analysis to 
determine the percentage of apoptotic cells (E).
Figure 3: The effect of metformin on the expression of Ki67 and Bcl-2 in bladder cancers development. Cancer tissues 
were collected from the animals treated with or without metformin and immunostaining was conducted with antibodies against Ki67 A. or 
Bcl-2 B. Magnifications: X400.
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Figure S2). These data suggest that metformin exerts 
its anticancer effects by slowing down cell growth and 
enhancing apoptosis.
Metformin selectively inhibits repopulation of 
bladder cancer stem cells
It has been suggested that bladder cancers arise from 
distinct urothelial sub-populations with CIS and invasive 
urothelial carcinoma arising from basal cells and papillary 
carcinomas deriving from intermediate cells. In order to 
determine if metformin exerts distinct effect on different 
precursor cells, we examined the expression of two stem 
cell markers, CK14 and OCT3/4 in tumors derived from 
animals treated with or without metformin. As shown in 
Figure 4 that metformin treatment reduced the number of 
CK14- (Figure 4A) and OCT3/4-positive cells (Figure 4B, 
Supplementary Table S4 and Supplementary Figure S2). 
On the other hand, at all time points examined (3, 6 and 12 
weeks) more CK20-positive cells were seen in the tissues 
of the animals treated with metformin (Supplementary 
Figure S1). It appears that metformin selectively inhibits 
CIS and invasive lesions without affecting papillary 
lesions. These data suggest that metformin may inhibit the 
repopulation of basal stem cell and subsequently repress 
early CIS and invasive cancer progression.
Metformin inhibits COX2/PGE2/STAT3 axis by 
downregulating COX2
Multiple lines of evidence suggest that PGE2 is 
an important inducer of CSC repopulation in different 
cancers including bladder cancer [42]. To dissect the 
mechanism of metformin inhibition of CK14- and 
OCT3/4-positive cell repopulation, we examined the effect 
of metformin on COX2, a key enzyme catalyzing the 
biosynthesis of PGE2. Figure 5A shows that metformin 
is capable of repressing the expression of COX2 at all 
time points in both papillary and invasive lesions. These 
observations were further substantiated by the dose-
dependent inhibition of COX2 in vitro when T24 cells 
were treated with different concentrations of metformin 
(Figure 6A). Consistent with COX2 inhibition, the levels 
of PGE2 in culture media were significantly lower when 
Figure 4: Metformin inhibits the repopulation of CSC. Bladder lesions from the model animals treated with or without metformin 
for different periods (3, 6 and 12 weeks) were analyzed by Immunohistochemical staining with antibodies against different stem cell 
markers CK14 A. and OCT3/4 B. Magnifications: X400.
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the cells were treated with metformin (Figure 6B). Based 
on the facts that in colorectal cancer the JAK2/STAT3 
signaling pathway is regulated by PGE2 [44], and STAT3 
is not only involved in the expansion of CK14-positive 
stem cells in bladder cancer [47], but STAT3 activation 
in urothelial stem cells also leads to invasive bladder 
cancer progression, we decided to examine if metformin-
inhibited bladder cancer development is through the 
COX2/PGE2/STAT3 axis. Immunohistochemistry (Figure 
5B, Supplementary Table S4 and Supplementary Figure 
S2) shows the levels of p-STAT3 in the bladder cancer 
animal model treated with metformin are consistently 
lower. These observations were further substantiated by 
the dose-dependent downregulation of phosphorylated 
STAT3 in cellular model (Figure 6A). Of note, metformin 
treatment has no effect on the levels of total STAT3. 
Consistent with downregulation of the levels of COX2 
and PGE2 as well as inhibition of STAT3 phosphorylation/
activation, the levels of both CK14 and OCT3/4 were 
repressed by metformin in a dose-dependent manner 
(Figure 6A); suggesting metformin may repress bladder 
cancer development through the COX2/STAT3 pathway.
To further substantiate our hypothesis, we treated 
T24 cells with either a COX2 specific inhibitor celecoxib, 
or different concentrations of metformin. As showed in 
Figure 6C, metformin repressed all above-mentioned 
factors as celecoxib did. In addition, we knocked down 
COX2 in T24 cells by siRNA technique and monitored 
the changes of the molecules including COX2, STAT3, 
p-STAT3, CK14 and OCT3/4. As shown in Figure 6D, 
both siCOX2-1 and siCOX2-3 knocked down COX2 
efficaciously but for some unknown reason that siCOX2-2 
failed to knock down COX2. When COX2 is knocked 
down (lanes 2 and 4 in Figure 6D), all three markers 
p-STAT3, CK14 and OCT3/4 were downregulated 
significantly. However, the total STAT3 levels were not 
affected at all. To demonstrate that metformin affects CSC 
repopulation through PGE2, we treated the cells with 
metformin in the presence or absence of exogenously 
added PGE2. Figure 6E shows that exogenously added 
PGE2 is able to counteract metformin and upregulate all 
CSC markers tested without affecting the levels of COX2; 
demonstrating the essentiality of PGE2 in bladder cancer 
stem cell repopulation. These data collectively suggest 
that metformin represses CK14+ stem cell repopulation 
by downregulating COX2 and subsequently inhibiting 
the COX2/PGE2/STAT3 axis. However, we noticed that 
high concentration (10mM) of metformin is capable of 
Figure 5: Metformin inhibits expression of COX2 and P-STAT3 in vivo. Immunohistochemical analyses of bladder lesions 
including mild, severe hyperplasia, invasive and papillary lesions from the rats of both MNU and MET groups in the sections with COX2 
A. and P-STAT3 B. at 3, 6,12 weeks. Magnifications: X400.
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inhibiting the levels of both CK14 and OCT3/4 by directly 
repressing STAT3 phosphorylation/activation even in the 
presence of exogenous PGE2, a phenomenon has been 
observed previously [37]. This suggests that metformin 
may also be able to repress bladder cancer development 
through a COX2-independent manner.
DISCUSSION
Using the MNU-induced rat orthotopic bladder 
cancer model we demonstrated the anti-tumor effects of 
metformin and explored its underlying mechanism with 
experiments in bladder cancer cell lines. Data from both 
in vitro and in vivo experiments suggest that metformin 
may not be able to prevent bladder cancer initiation 
but it appeared to be capable of slowing down the 
progression both from mild to moderate/severe dysplasia 
lesions and from CIS lesions to invasive lesions. By 
directly downregulating COX2, metformin is able to 
downregulate the level of PGE2, which subsequently 
leads to reduced STAT3 phosphorylation/activation. 
Attenuated STAT3 signaling pathway results in reduced 
levels of cyclinD1 and Bcl-2, which caused cancer cells 
being arrested in G1/S phases and ultimately apoptotic 
cell death. Based on these findings, we proposed that 
metformin suppressed bladder cancer development by 
inhibiting cancer stem cell repopulation via the COX2/
PGE2/STAT3 axis (Figure 7).
Carcinogen-induced rat bladder tumor is a 
well-established model system, which has been widely 
used in bladder cancer researches for decades. BBN 
(N-butyl-N-(4-hydroxybutyl) nitrosamine), MNU 
(N-methyl-N-nitrosourea) and FANFT (N-[4-(5-nitro-2-
furyl)-2-thiazolyl]-formamide) are the most commonly-
used carcinogenic inducers. Compared to the models 
induced by BBN and FANFT, both of them must be taken 
orally, establishing the MNU-induced model is much 
easier, quicker and cheaper [48]. On the other hand, 
comparing to cell transplantation model, tumors in animal 
models more closely represent human bladder tumors in 
histology, biochemical properties, molecular and genetic 
characteristics, natural history and biological behavior. 
In addition, the carcinogen-induced tumor is a more ideal 
system for studying both tumor initiation and progression 
including dysplasia, CIS, papillary and invasive cancers. 
It is the animal model that enabled us to differentiate the 
effects of metformin on tumor progression from initiation. 
Therefore, we believe that this model system would also 
be more ideal in studying the pathogenesis, prevention and 
potential bladder cancer therapies.
Figure 6: Effect of metformin on COX2/PGE2/STAT3 axis. A. and B. T24 cell was seeded in 6-well plates and serum-starved 
for 24 h before exposed to metformin (0, 1, 5, 10, and 20 mM) for 24 h. Cell lysates were assayed by western blot with antibodies against 
CK14, OCT3/4, COX2, P-STAT3 or STAT3 (A), and the culture media were collect for ELISA assays (B). C, D. and E. T24 cells were 
treated with either celecoxib (20 μM) or metformin (1, 10 mM) for 24 h (C), and transfected with three siRNAs against COX2 and one for 
negative control and the cells were cultured for 48 h (D), The cells were treated by PGE2 (10 µM) with or without metformin (1, 10 mM) 
for 24 h (E). Cell lysates were assayed by western blot with antibodies against CK14, OCT3/4, COX2, P-STAT3 or STAT3.
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It has been noticed recently that the anticancer effect 
of metformin may rely on its role in CSC inhibition [49]. 
Metformin inhibits CSCs repopulation in different cancers 
including colon cancer [50], pancreatic [51], esophageal 
cancer [52], skin cancer [53] and ovarian cancer [54]. 
CSCs are a sub-population of cancer cells responsible for 
tumor initiation, differentiation, recurrence, metastasis, 
and drug resistance [20]. Patients with muscle-invasive 
bladder cancer showed higher recurrence rate and poor 
survival. Furthermore, it is believed that CSCs play 
important roles in the development of resistance to 
multiple chemotherapies [20]. There are many well-
established CSC markers, including cytokeratin 5 (CK5), 
cytokeratin 14 (CK14) and aldehyde dehydrogenase 
1 family, member A1 (ALDH1A1). In human bladder 
cancer, the primitive stem cell marker CK14 also serves 
as the precursor of CK5 [12]. This means that CK14+ cells 
are scattered and represent only a subpopulation of CK5+ 
urothelial cells. We found that metformin is able to dose-
dependently repress CK14+ cells in animal model and 
downregulate the levels of CK14 in bladder cancer cell 
lines. To our knowledge, we are the first to systemically 
demonstrate that metformin inhibits bladder cancer 
development by directly targeting CSC repopulation.
It has been well-established that metformin plays 
important roles in different signaling pathways, including 
AMPK/mTOR [36], TGF-β/IL-6 [56], Wnt/β-catenin 
[57]; autophagy pathway [58], EMT [30]. The current 
body of evidence is inadequate to establish an absolute 
protective role of metformin in bladder cancer [59]. But 
in consistence with that reported by Pan et all [37], our 
results support the notion that metformin represses bladder 
cancer development through STAT3 signaling pathway. In 
addition to that, we demonstrated that metformin inhibits 
bladder cancer cell growth and enhances apoptosis by 
downregulating cyclinD1 and Bcl-2. Also consistent 
with that reported by Zhang et al [36], we showed that 
metformin dose-dependently arrests bladder cancer cells 
in G1/S phases and subsequent apoptosis. Based on the 
fact that (1) metformin is able to inhibit COX2 [60]; 
Figure 7: Schematic model of the hypothesized mechanism by which metformin inhibits bladder cancer.
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(2) PGE2, a product catalyzed by COX2, is capable of 
promoting stem cell expansion [61] and mobilization [62]; 
and (3) blocking PGE2 abrogates bladder cancer chemo-
resistance by repressing CK14+ cells repopulation [62], 
we explored the possibility of metformin effect on COX2/
PGE2 pathway and found that metformin is indeed capable 
of downregulating COX2 and subsequently reducing the 
level of PGE2. Since STAT3, a downstream target of 
COX2/PGE2, is involved in the regulation of primitive 
CK14+ cell expansion [47], we propose that in bladder 
cancer metformin inhibits CK14+ cell repopulation 
through the COX2/PGE2/STAT3 axis.
In conclusion, to our best knowledge that we are the 
first to use both cell and animal models to systemically 
demonstrate that metformin inhibits bladder cancer 
progression by inhibiting cancer stem cell repopulation 
through the COX2/PGE2/STAT3 axis. Given the fact 
that metformin is capable of repressing bladder cancer 
progression, administration of metformin to bladder cancer 
patients may extend therapeutic period for application of 
other cancer treatments.
MATERIALS AND METHODS
Metformin and N-methyl-N-nitrosourea (MNU) 
treatment protocol
Adult female SD rats at 5-6 weeks of age 
were obtained from Animal Experimental Center of 
Daping Hospital, Third Military Medical University 
(Chongqing, China) and housed in the research center. 
Animal experiments in this study were approved by the 
Institutional Animal Care and Use Committee of Third 
Military Medical University. Animals were fed with 
standard laboratory rat chow with free access of tap 
water. Rats were divided into three groups: control group; 
N-methyl-N-nitrosourea-treated group (MNU group); 
and MNU + metformin (MET group) (Figure 1A). For 
MNU treatment, 2.5 mg of MNU (SICHUAN HANOVI 
TECHNOLOGY) dissolved in sodium citrate buffer (5 
g/L) was irrigated into the rat bladders via epidural catheter 
every 3 weeks (i.e. week 0, 3, 6, 9). The rats in MET group 
access tap water with metformin (1 g/L) freely. Rats were 
sacrificed at week 3 (n=30), week 6 (n=26), and week 12 
(n=44), respectively. Blood was drawn from each rat and 
used for glucose measurement. The bladders were fixed 
in 10% formalin and paraffin embedded for hematoxylin 
and eosin (H&E) and immunostaining examination was 
conducted by Hualiang Xiao, a certificated pathologist.
Immunostaining
Tumor specimens were fixed in 10% formaldehyde 
solution and embedded in paraffin, and sections 
were mounted onto glass slides. Sections were then 
deparaffinized in xylene, re-hydrated through ethanol, and 
heated for 30 min to enhance the heat-induced antigen 
retrieval. To block non-specific reactions, slides were 
blocked in respective serum at 4°C overnight. Primary 
antibodies against Ki67 (1:300 Origene), CK14(1:100 
Abcam) and CK20 (1:400 Abcam), OCT3/4 (1:200 
Santa Cruz Biotech-nology), COX2 (1:400 Origene), 
p-STAT3(Tyr705) (1:100 Cell signaling) and Bcl-2 
(1:100 Santa Cruz Biotech-nology) were used. Tissue 
sections were incubated with each antibody overnight 
at 4°C, and then incubated with horseradish peroxidase-
conjugated anti-rabbit, anti-mouse or anti-goat IgG 
secondary antibodies. Slides were subsequently treated 
with a streptavidinperoxidase reagent and incubated 
in phosphate-buffered salinediaminobenzidine and 1% 
hydrogen peroxide, followed by counterstaining with 
Mayer’s haematoxylin.
Cell culture and viability assay (MTT)
Human bladder cancer cells (T24 and RT4) were 
obtained from Cell Bank of Shanghai Institiutes for 
biological Sciences (Chinese Academy of Sciences), 
and cultured in DMEM, High Glucose (Hyclone) 
supplemented with 10% FBS (Gibico) at 37°C with 5% 
carbon dioxide. Viability assays were conducted with 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT) dye (5 mg/ml, Sigma). The density 
of the solubilized formazan was read at 490 nm 
spectrophotometrically (Bio-Rad, Hercules, and CA)
Analysis of cell cycle and apoptosis
T24 Cells were seeded in 75 cm2 flasks and serum-
starved for 24 h. Metformin was added to the culture to 
final concentrations of 0, 1, 5, 10, 20 mM and incubated 
for 24 h. Cells were washed with cold PBS for three times, 
resuspended in 70% ethanol used for analysis of cell cycle 
distribution, or directly Annexin V binding buffer used for 
analysis of apoptosis status.
Western blotting
T24 or RT4 cells were seeded in 6-well plates 2×105 
cells/well, treated with corresponding reagents, including 
metformin (0, 1 mM, 5 mM, 10 mM, 20 mM), Celecoxib (20 
μM YUANYE BioTECH, Shanghai, China) and PGE2(10 
μM, Sigma). Cell lysates were separated on SDS-PAGE 
followed by western blotting assay as described [26] with 
the following primary antibodies: Bcl-2 (1:1000 Epitomics), 
Cyclin D1 (1:1000 Fantibody, China), CK14 (1:400 Abcam), 
STAT3 (1:2000 Abcam), OCT3/4 (1:400 Santa Cruz Biotech-
nology), COX2 (1:2000 Origene), p-STAT3 (Tyr705) (1:2000 
Cell Signaling), AMPK (1:700 Proteintech), p-AMPK 
(1:1000 Cell Signaling) and β-actin (1:5000 Cell Signaling).
Oncotarget28244www.impactjournals.com/oncotarget
PGE2 ELISA assay
T24 Cells were seeded in 6-well plates and serum-
starved for 24 h. Different concentrations (0, 1, 5, 10, 
20 mM) of metformin was added into the media and 
cultured for 24 hours. The supernatant was collected and 
prostaglandin E2 (PGE2) released to the culture media was 
measured using commercially available enzyme-linked 
immunosorbent assay (ELISA) kits from Cloud-clone corp.
COX-2 siRNA transfection
As reported previously [63], the following primers 
were obtained from Shanghai Genechem Co., LTD (China): 
scramble siRNA (MOCK) sense sequence 5’-CCU ACG CCA 
CCA AUU UCG U-3’, antisense sequence 5’-ACG AAA 
UUG GUG GCG UAG G-3’; and COX-2 siRNA : siCOX2-1 
sense sequence 5’-CAG AUG AAA UAC CAG UCU U-3’, 
antisense sequence 5’-AAG ACUGGU AUU UCA UCU 
G-3’; siCOX2-2 sense sequence 5’-GAG GUU AAU GAA 
GUA CCA A-3’,, antisense sequence 5’-UUG GUA CUU 
CAU UAA CCU C-3’; and siCOX2-3 sense sequence 5’-
CAC CAA GAG UAU AAA CCU U-3’, antisense sequence 
5’-AAG GUU UAU ACU CUU GGU G-3’. T24 cells were 
plated at 80% confluence in 6-well plates and then starved 
with serum deprivation for 24 h. Before transfection, diluted 
5 μl lipo2000 was added into diluted siRNA, and then the mix 
was added into the medium. The cells were transfected for 48 
h, then lysed for western blot.
Statistical analysis
GraphPad Prism 5.0 was used for all statistical 
analyses. Data were presented as means±Standard 
deviation (SD). In all of the tests, a P-value of less than 
0.05 was considered statistically significant.
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